Genfit S.A. - Asset Resilience Ratio
Genfit S.A. (GNFT) has an Asset Resilience Ratio of 64.01% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Explore Genfit S.A. strategic investment ratio to see how much of total assets are deployed in long-term investments.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2024)
This chart shows how Genfit S.A.'s Asset Resilience Ratio has changed over time. See defensive interval ratio of Genfit S.A. to measure how many days the company can operate on defensive assets alone.
Liquid Assets Composition Over Time
This chart breaks down Genfit S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Genfit S.A..
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €101.09 Million | 64.01% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €101.09 Million | 64.01% |
Asset Resilience Insights
- Very High Liquidity: Genfit S.A. maintains exceptional liquid asset reserves at 64.01% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Genfit S.A. Industry Peers by Asset Resilience Ratio
Compare Genfit S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
BRITANNIA LIFE SCIENCES
F:L020 |
Biotechnology | 63.76% |
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
ABCELLERA BIOLOGICS
F:8QQ |
Biotechnology | 29.87% |
Annual Asset Resilience Ratio for Genfit S.A. (2004–2024)
The table below shows the annual Asset Resilience Ratio data for Genfit S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 42.40% | €64.21 Million ≈ $75.07 Million |
€151.42 Million ≈ $177.03 Million |
+3.56pp |
| 2023-12-31 | 38.84% | €67.53 Million ≈ $78.95 Million |
€173.87 Million ≈ $203.27 Million |
-18.52pp |
| 2022-12-31 | 57.36% | €123.64 Million ≈ $144.55 Million |
€215.54 Million ≈ $251.99 Million |
+33.13pp |
| 2021-12-31 | 24.23% | €68.26 Million ≈ $79.80 Million |
€281.72 Million ≈ $329.36 Million |
-59.37pp |
| 2020-12-31 | 83.60% | €166.03 Million ≈ $194.11 Million |
€198.61 Million ≈ $232.20 Million |
-1.33pp |
| 2019-12-31 | 84.93% | €263.15 Million ≈ $307.65 Million |
€309.85 Million ≈ $362.25 Million |
-5.69pp |
| 2016-12-31 | 90.61% | €150.61 Million ≈ $176.08 Million |
€166.21 Million ≈ $194.32 Million |
+90.58pp |
| 2015-12-31 | 0.03% | €22.00K ≈ $25.72K |
€69.26 Million ≈ $80.97 Million |
-4.61pp |
| 2014-12-31 | 4.64% | €4.01 Million ≈ $4.69 Million |
€86.37 Million ≈ $100.97 Million |
+4.64pp |
| 2013-12-31 | 0.00% | €400.00 ≈ $467.64 |
€29.15 Million ≈ $34.08 Million |
-0.07pp |
| 2012-12-31 | 0.08% | €18.00K ≈ $21.04K |
€23.58 Million ≈ $27.57 Million |
+0.03pp |
| 2011-12-31 | 0.05% | €13.80K ≈ $16.13K |
€29.08 Million ≈ $33.99 Million |
-1.96pp |
| 2008-12-31 | 2.00% | €921.40K ≈ $1.08 Million |
€45.99 Million ≈ $53.77 Million |
-1.85pp |
| 2007-12-31 | 3.85% | €1.55 Million ≈ $1.81 Million |
€40.21 Million ≈ $47.01 Million |
+0.60pp |
| 2006-12-31 | 3.25% | €1.50 Million ≈ $1.76 Million |
€46.24 Million ≈ $54.06 Million |
-2.21pp |
| 2005-12-31 | 5.46% | €1.68 Million ≈ $1.97 Million |
€30.83 Million ≈ $36.05 Million |
-33.51pp |
| 2004-12-31 | 38.96% | €11.93 Million ≈ $13.94 Million |
€30.61 Million ≈ $35.78 Million |
-- |
About Genfit S.A.
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fi… Read more